---
title: "Higher systemic GLP1R expression linked to lower Parkinson’s risk in GLP-1RA–treated type 2 diabet"
id: "pubmed-41967915"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-41967915"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/41967915/"
doi: "10.1093/brain/awag130"
published_at: "2026-10-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Higher systemic GLP1R expression linked to lower Parkinson’s risk in GLP-1RA–treated type 2 diabet
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-41967915
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/41967915/)
- **DOI:** [10.1093/brain/awag130](https://doi.org/10.1093%2Fbrain%2Fawag130)
- **Published At:** 2026-10-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This electronic health record new-user cohort study used the NIH All of Us Research Program to evaluate whether interindividual differences in systemic **GLP1R** expression are associated with risk of **Parkinson’s disease and related disorders (PDRD)** among adults with type 2 diabetes initiating **GLP-1 receptor agonists (GLP-1RAs)**. - The analytic sample included 7,039 GLP-1RA initiators aged ≥50 years with no prior PDRD or Alzheimer’s disease and related dementias (ADRD), who started treatment between 2005 and 2023. - Systemic GLP1R expression was proxied genetically by a 15-variant cis-expression quantitative trait locus (cis-eQTL) genetic risk score; participants were dichotomized at the cohort median into high versus low genetic score groups (3,520 high; 3,519 low). - Median follow-up was 3.8 ± 3.1 years; follow-up ended at incident PDRD, death, or 1 October 2023. - Compared with the low-score group, the high-score group had a lower hazard of incident PDRD (multivariable-adjusted HR 0.78, 95% CI 0.62–0.98) and a lower incidence rate (rate difference −1.36 per 1,000 person-years; 95% CI −2.51 to −0.20). - Associations persisted across prespecified sensitivity analyses that excluded early outcome events and short drug exposure, indicating robustness of the primary finding. - No association was observed between the GLP1R genetic score and incident ADRD (HR 1.02, 95% CI 0.81–1.28); ADRD was evaluated as an exploratory outcome. - Authors conclude that a mechanism-anchored genetic proxy for higher systemic **GLP1R** expression is linked to lower incident PDRD risk among GLP-1RA–treated adults with type 2 diabetes and suggest systemic GLP1R-mediated pathways may contribute to interindividual differences in PDRD risk. - The study indicates that genetic instruments for **GLP1R expression** could inform hypotheses and design for future PDRD clinical trials, while details such as specific agents, dosing, and some sensitivity-analysis metrics were not reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/41967915/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41967915%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/41967915/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/41967915/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/41967915/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/41967915/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/41967915/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41967915%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41967915%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/41967915/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41967915/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41967915/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/41967915/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--academic.oup.com-images-oup_pubmed.png) Silverchair Information Systems ](https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awag130 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/41967915/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41967915/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/41967915/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/41967915/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/41967915/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/41967915/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/41967915/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/41967915/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/41967915/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/41967915/#linkout) Title & authors Abstract Similar articles MeSH terms Substances Related information Grants and funding LinkOut - more resources Brain Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Brain%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Brain%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) . 2026 Oct 5;149(10):3431-3439. doi: 10.1093/brain/awag130. # GLP1R expression and Parkinson's disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes [Kyung Ah Woo](https://pubmed.ncbi.nlm.nih.gov/?term=Woo+KA&cauthor_id=41967915)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-1 "Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-2 "Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea."), [Yoonhyuk Jang](https://pubmed.ncbi.nlm.nih.gov/?term=Jang+Y&cauthor_id=41967915)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-2 "Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-4 "Department of Immunology, Harvard Medical School, Boston, MA 02115, USA."), [Han-Joon Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+HJ&cauthor_id=41967915)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea."), [Peter J Park](https://pubmed.ncbi.nlm.nih.gov/?term=Park+PJ&cauthor_id=41967915)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#full-view-affiliation-1 "Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.") Affiliations Expand ### Affiliations * 1 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA. * 2 Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea. * 3 Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. * 4 Department of Immunology, Harvard Medical School, Boston, MA 02115, USA. * PMID: **41967915** * DOI: [ 10.1093/brain/awag130 ](https://doi.org/10.1093/brain/awag130) Item in Clipboard # GLP1R expression and Parkinson's disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes Kyung Ah Woo et al. Brain. 2026. Show details Display options Display options Format Abstract PubMed PMID Brain Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Brain%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Brain%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) . 2026 Oct 5;149(10):3431-3439. doi: 10.1093/brain/awag130. ### Authors [Kyung Ah Woo](https://pubmed.ncbi.nlm.nih.gov/?term=Woo+KA&cauthor_id=41967915)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-1 "Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-2 "Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea."), [Yoonhyuk Jang](https://pubmed.ncbi.nlm.nih.gov/?term=Jang+Y&cauthor_id=41967915)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-2 "Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-4 "Department of Immunology, Harvard Medical School, Boston, MA 02115, USA."), [Han-Joon Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+HJ&cauthor_id=41967915)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-3 "Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea."), [Peter J Park](https://pubmed.ncbi.nlm.nih.gov/?term=Park+PJ&cauthor_id=41967915)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41967915/#short-view-affiliation-1 "Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.") ### Affiliations * 1 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA. * 2 Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea. * 3 Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. * 4 Department of Immunology, Harvard Medical School, Boston, MA 02115, USA. * PMID: **41967915** * DOI: [ 10.1093/brain/awag130 ](https://doi.org/10.1093/brain/awag130) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Preclinical and epidemiologic data suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of Parkinson's disease and related disorders (PDRD), yet clinical trial findings have been mixed, raising the possibility of biologically meaningful heterogeneity. We tested whether interindividual differences in systemic GLP1R expression are associated with PDRD risk among adults with type 2 diabetes initiating GLP-1RAs. We conducted an electronic health record-based new-user cohort study in the National Institutes of Health All of Us Research Program, focusing on adults with type 2 diabetes aged 50 years or older who initiated a GLP-1RA between 2005 and 2023 and had no prior PDRD or Alzheimer's disease and related dementias (ADRD). Systemic GLP1R expression was genetically proxied by a 15-variant cis-expression quantitative trait locus (cis-eQTL) genetic risk score dichotomized at the cohort median. Follow-up ended at the earliest of incident PDRD, death or 1 October 2023. Hazard ratios (HR) were estimated using multivariable Cox proportional hazards models adjusting for baseline covariates, and incidence rates and rate differences per 1000 person-years were estimated using Poisson models. Prespecified sensitivity analyses excluded early outcome events and short drug exposure; an exploratory analysis evaluated incident ADRD. The cohort included 7039 initiators (3520 high versus 3519 low genetic score; mean age 61.7 ± 8.4 years; 59.8% female; mean follow-up 3.8 ± 3.1 years). Compared with the low-score group, the high-score group had a lower hazard of incident PDRD [HR 0.78; 95% confidence interval (CI) 0.62 to 0.98] and a lower incidence rate (rate difference -1.36 per 1000 person-years; 95% CI -2.51 to -0.20). Associations were consistent across sensitivity analyses. No association was observed for incident ADRD (HR 1.02; 95% CI 0.81 to 1.28). These findings link a mechanism-anchored genetic proxy for higher systemic GLP1R expression to a lower risk of incident PDRD among GLP-1RA-treated adults with type 2 diabetes. Systemic GLP1R-mediated pathways may be relevant to interindividual differences in observed PDRD risk, and genetic instruments for GLP1R expression may inform hypotheses for future PDRD trial design. **Keywords:** GLP1R; Parkinson’s disease; genetics; glucagon-like peptide-1 receptor agonist; type 2 diabetes. © The Author(s) 2026. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study. ](https://pubmed.ncbi.nlm.nih.gov/39189078/) Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, Huang Y, Armstrong M, Svensson M, Virnig BA, DeKosky ST, Bian J, Guo J.Tang H, et al.Mov Disord. 2024 Nov;39(11):1960-1970. doi: 10.1002/mds.29992. Epub 2024 Aug 27.Mov Disord. 2024.PMID: 39189078Free PMC article. * [ Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study. ](https://pubmed.ncbi.nlm.nih.gov/41075815/) Wu JY, Lin YM, Hsu WH, Liu TH, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.Wu JY, et al.J Am Med Dir Assoc. 2025 Dec;26(12):105901. doi: 10.1016/j.jamda.2025.105901. Epub 2025 Oct 29.J Am Med Dir Assoc. 2025.PMID: 41075815 * [ Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study. ](https://pubmed.ncbi.nlm.nih.gov/40897378/) Olbrich H, Kridin K, Zirpel H, Hernandez G, Sadik CD, Gaffal E, Thaçi D, Ludwig RJ.Olbrich H, et al.Br J Dermatol. 2026 Jan 6;194(1):59-66. doi: 10.1093/bjd/ljaf346.Br J Dermatol. 2026.PMID: 40897378 * [ Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson's disease in patients with type 2 diabetes: A propensity score-matched cohort study with meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/40976497/) Yeh JA, Lin SM, Liu YC, Hsu JZ, Huang AH, Munir KM, Peng CC, Loh CH, Huang HK.Yeh JA, et al.Diabetes Res Clin Pract. 2025 Nov;229:112914. doi: 10.1016/j.diabres.2025.112914. Epub 2025 Sep 19.Diabetes Res Clin Pract. 2025.PMID: 40976497 * [ Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. ](https://pubmed.ncbi.nlm.nih.gov/36321557/) Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Crider K, et al.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.Cochrane Database Syst Rev. 2022.Update in: [Cochrane Database Syst Rev. 2026 Feb 18;2:CD014217. doi: 10.1002/14651858.CD014217.pub2.](https://pubmed.ncbi.nlm.nih.gov/41705996/)PMID: 36321557Free PMC article.Updated. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=41967915) ## MeSH terms * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Cohort Studies Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cohort+Studies%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cohort+Studies) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Diabetes Mellitus, Type 2* / complications Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fcomplications%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Diabetes Mellitus, Type 2* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Diabetes Mellitus, Type 2* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Glucagon-Like Peptide-1 Receptor Agonists* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor+Agonists) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41967915/) * Glucagon-Like Peptide-1 Receptor* / biosynthesis Actions * [ Search in PubMed ](https:/
## Related Clinical Research

- [Olive oil before carbs and blood sugar: what the mouse study found](https://medichelpline.com/clinical-feed/medical-news-today-0-olive-oil-shot-trend-what-science-really-says-about-fat-and-glucose-response.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [GLP-1 receptor agonists and reduced dementia risk in patients with CKD and type 2 diabetes](https://medichelpline.com/clinical-feed/pubmed-41697144.md) (DOI: 10.1093/ndt/gfag032)
- [Regional 7T 31P‑MRSI Reveals Segmental Myocardial Energetic Impairment in Cardiovascular Disease](https://medichelpline.com/clinical-feed/medrxiv-6-regional-cardiac-31p-mrsi-at-7t-detection-of-spatially-heterogeneous-patterns.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.